Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

A follow-up of the ShortHER trial suggests tumor-infiltrating lymphocytes (TILs) can help identify patients who may benefit ...

Ado-trastuzumab emtansine led to improved overall survival and invasive disease–free survival over trastuzumab in patients ...

After a phase 3 study showed a promising pCR rate with HLX11, the pertuzumab biosimilar’s BLA has been accepted for review by the FDA.

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal ...

Tevimbra plus chemotherapy improved overall survival in patients with advanced ESCC, with 68.3% achieving a response. Median time to response was 6.1 weeks, with most responses occurring within eight ...

Chemotherapy-induced hair loss can be quite upsetting for many people. While this type of hair loss is typically temporary, it may take a considerable amount of time for hair to grow back to its ...

Chemotherapy is a common treatment for cancer, but determining its effectiveness can be complex. There are key signs, tests, and factors to help you understand if chemotherapy is working and how ...

Medicare also pays for some chemotherapy drugs through Part D. A person with Medicare Advantage, also known as Medicare Part C, must have at least the same coverage as a person with Original ...

The addition of trastuzumab and pertuzumab to chemotherapy was associated with increased toxicity in patients with HER2-positive gastric cancers enrolled in the INNOVATION trial. In patients with HER2 ...

Trastuzumab deruxtecan demonstrated a higher objective response rate of 62.6% compared to 34.4% with chemotherapy. Approximately 85%-90% of HR-positive, HER2-negative cases had actionable HER2 ...